The mechanisms of action and resistance of valemetostat, an EZH1–EZH2 dual inhibitor, in patients with adult T cell leukaemia/lymphoma who initially responded but later showed disease progression are explored. This evidence concerns the gene EZH2 and adult T-cell leukemia/lymphoma.